Archon, a Seattle, WA-based biotechnology company providing computationally designed Antibody Cages (AbCs), raised $20M in Seed funding.
The round was led by Madrona Ventures with participation from DUMAC Inc., Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Venture Investments and Cornucopian Capital.
The company intends to use the funds to expand operations and its business reach.
Led by CEO James Lazarovits, Archon is a biotechnology company developing computationally designed proteins to unlock therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. It directly applies generative protein design to rapidly manufacture Antibody Cages (AbCs), a new class of biologics with unique potency and differentiated biodistribution. AbCs integrate the unparalleled binding affinity and specificity of antibodies into novel self-assembling nanostructures designed to overcome the most difficult challenges in drug development.
FinSMEs
30/10/2024